University of Cambridge leaders have issued a stark warning: the UK risks lagging behind in the commercialisation of world-class research unless it enhances support for academic spin-out companies struggling to scale.
At a London showcase featuring Cambridge’s most promising spin-outs, university officials and venture capitalists observed that while Britain remains a hub of scientific excellence, it lacks the investment firepower and infrastructure to transform groundbreaking research into global businesses.
Gerard Grech, managing director of Founders, a Cambridge initiative to [boost entrepreneurial growth](https://bmmagazine.co.uk/in-business/uks-entrepreneurial-ambitions-stronger-than-ever-as-small-business-growth-outpaces-larger-companies/), stated: “The world isn’t waiting for UK and European science to commercialise. Founders in Silicon Valley, Shenzhen and Bangalore are building rapidly. The question is: can European universities match that pace without losing the depth that makes our research world-class?” He highlighted that significant commercial opportunities arise when university science meets bold capital, emphasizing: “This is where real innovation happens.”
Cambridge’s vice-chancellor, Deborah Prentice, underscored the university’s strong track record in spin-out formation, noting that last year, Cambridge spin-outs raised over $2 billion and now produce more spin-outs per capita than any other UK university. “Cambridge is by many measures the highest-performing innovation ecosystem in Europe,” she said. “International investors, large companies and world-class scientists recognise that we’re punching above our weight — but we need to go further.”
The challenge, however, lies in scaling these ventures into globally competitive firms. Data from Dealroom, presented at the event, showed that although Cambridge has a robust pipeline of start-ups with up to $10 million in venture capital, the number of firms advancing to raise $100 million or more is considerably lower than in Silicon Valley.
Suranga Chandratillake, general partner at Balderton Capital, remarked: “That is the problem. It is as simple as that. You can build so much with $10 million, $20 million, or $30 million. But you need hundreds of millions to create truly global, category-defining companies. And we just don’t have enough companies raising that kind of money.”
The showcase featured pitches from several early-stage, high-impact ventures tackling complex medical issues. Prodromic is developing predictive diagnostics for early detection of brain diseases like dementia, while Gastrobody Therapeutics is creating ingestible, stable antibodies for gastrointestinal diseases such as Crohn’s, potentially eliminating the need for injections.
These innovations highlight the commercial potential within UK universities. Still, investors and academics warned that without scaling follow-on capital, these businesses might not realise their full potential — or may relocate abroad.
Cambridge’s message was unequivocal: for the UK to convert scientific leadership into economic leadership, it must urgently enhance its ability to fund, grow, and retain its most promising ventures. With international capital accelerating elsewhere, and breakthrough research already occurring on British soil, the missing element is not invention — it’s investment at scale.
Read more:
[Cambridge warns UK must scale up investment to turn spin-outs into global success stories](https://bmmagazine.co.uk/news/cambridge-warns-uk-must-scale-up-investment-to-turn-spin-outs-into-global-success-stories/)
